Loading company…
Maryland cell therapeutics company using Flow Electroporation platforms to develop and commercialize cell-based medicines.
Founded in 1998 and based in Maryland, US, MaxCyte, Inc. develops and commercializes cell-based medicines using its Flow Electroporation platforms, including ATx, STx, GTx and ExPERT. It was founded by CEO and President Doug Doerfler, and reported annual revenue of USD 26.17 million as of 2020. The company has raised USD 29.95 million from Harbert Growth Partners, Tall Oaks Capital Partners and Intersouth Partners, and is listed on NASDAQ under MXCT.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in